search
Back to results

The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss

Primary Purpose

Overweight

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
High protein, high fiber dietary supplement
Placebo
Sponsored by
Beachbody
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Overweight focused on measuring protein, fiber, weight loss, fat loss

Eligibility Criteria

25 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female of 25-50 years of age
  2. If female, the subject is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR

    Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result at screening. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) for at least 3 months
    • Double-barrier method
    • Non-hormonal IUDs
    • Hormonal IUD methods must be a stable dose for at least 3 months
    • Vasectomy of partner
    • Non-heterosexual lifestyle
  3. A BMI between 27.0 - <35.0 kg/m2 (inclusive). Subjects must meet exactly the inclusion BMI at screening, or be screen failed. Subjects who meet the BMI requirement at screening and present at run-in with a BMI of <27.0 or >35 kg/m2 will be counselled.
  4. Subjects that have had a stable weight for the past 6 months. A stable weight is defined as not having gained or lost more than 5 kg of body weight throughout the past 6 months (cycling of weight, for example, continuously up and down anything less than 5 kg is considered stable)
  5. Agreement to comply with dietary recommendations from nutritionist throughout the duration of the study that include a 500 kcal energy deficit from their predicted total energy requirements
  6. Agrees to fully comply with all study procedures
  7. Has given voluntary written and informed consent to participate in the study
  8. Determined to be healthy as per laboratory parameters and physical examination

Exclusion Criteria:

  1. Females who are pregnant, breastfeeding or planning to become pregnant during the course of the study
  2. Subjects who are smokers (tobacco, e-cigarettes) or have been a smoker within the past 1 year from screening
  3. Individuals who carry an epi-pen, or those with a diagnosed allergy or who believe that they have an allergy to milk or milk products, crustacean shellfish, tree nuts, or peanuts
  4. Individuals with a severe allergy to egg, fish, wheat or soy ingredients as the product is manufactured in a facility that contains these ingredients
  5. The use of prescription, over-the-counter health products, or natural health products/dietary supplements being taken for weight loss, cholesterol levels, or blood pressure within 4 weeks of screening
  6. Subjects with a history of eating disorders
  7. Current participation or participation within the last 3 months in any weight loss program or diet (for example Weight Watchers, Jenny Craig, DASH diet, Atkins, Mediterranean etc.)
  8. Medical history of thyroid disorders except for subjects diagnosed with hypothyroid and have been on stable medication for at least the last 3 months prior to enrollment. All subject with medical history of hyperthyroid are excluded
  9. Medical history of hypercholesterolipidemia
  10. Use of cholesterol lowering prescription drugs within the last 6 months
  11. Fasting TGs ≥ 200 mg/dL (2.26 mmol/L) or a fasting total cholesterol ≥ 240 mg/dL (6.216 mmol/L)
  12. Fasting glucose ≥ 126 mg/dL
  13. Hypertension defined as untreated systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg, or the use of prescription high blood pressure/hypertension medications within the last 6 months
  14. Type I or Type II diabetes or use of diabetes medication in a preventative setting.
  15. History of gastrointestinal dysfunction or surgery that may influence digestion or absorption
  16. Chronic inflammation or structural abnormality, including history of, of the digestive tract (inflammatory bowel disease, celiac disease, chronic diarrhea, chronic constipation, duodenal or gastric ulcer, gastric retention or obstruction, Gastroesophageal reflux disease (GERD), or symptomatic cholelithiasis)
  17. Subjects who have a history of colorectal cancer, bowel resection, rectocele, or colostomy
  18. Immunocompromised individuals such as subjects that have undergone organ transplantation, those with rheumatoid arthritis, or subjects diagnosed with human immunodeficiency virus (HIV)
  19. Unstable medical conditions that in the opinion of the Qualified Investigator preclude the subject from participating in the study
  20. Anti-anxiety and anti-psychotic medications will be assessed by the MD on a case by case basis
  21. Alcohol use > 2 standard alcoholic drinks per day
  22. Alcohol or drug abuse within the last 6 months
  23. Use of medicinal marijuana
  24. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative
  25. Subjects with metal fixation plates or screws from a previous surgery
  26. Clinically significant abnormal laboratory results at screening
  27. Participation in a clinical research trial within 30 days prior to randomization
  28. Allergy or sensitivity to study supplement ingredients
  29. Individuals who are cognitively impaired and/or who are unable to give informed consent
  30. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
  31. Unwilling or unable to comply with study timeline and procedures
  32. Individuals who do not like the taste of chocolate or shake type drinks

Sites / Locations

  • Great Lakes Clinical Trials (of MB Clinical Research and Consulting, LLC)
  • KGK Synergize Inc.
  • GI Labs, Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

High protein, high fiber

Low protein, low fiber

Arm Description

Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks

Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks

Outcomes

Primary Outcome Measures

Change in body weight (kg)
Body weight measured by clinic study staff at required visits
Change in body fat percentage (%)
Body fat percentage as determined by dual x-ray absorptiometry (DXA)

Secondary Outcome Measures

Change in total fat mass (kg)
Body fat mass as determined by DXA
Change in total lean mass (kg)
Body lean mass as determined by DXA
Change in percent abdominal fat (%)
Abdominal fat percentage as determined by DXA
Change in percent android fat (%)
Android fat percentage as determined by DXA
Change in percent gynoid fat (%)
Gynoid fat percentage as determined by DXA
Change in percent trunk fat (%)
Trunk fat percentage as determined by DXA
Change in percent leg fat (%)
Leg fat percentage as determined by DXA
Change in body weight (kg)
Body weight measured by clinic study staff at required visits
Change in body weight (kg)
Body weight measured by clinic study staff at required visits
Change in Waist circumference (cm)
measured with a tape measure at the part of the trunk located midway between the lower costal margin and the iliac crest while the person is standing
Change in Waist circumference (cm)
measured with a tape measure at the part of the trunk located midway between the lower costal margin and the iliac crest while the person is standing
Change in Waist circumference (cm)
measured with a tape measure at the part of the trunk located midway between the lower costal margin and the iliac crest while the person is standing
Change in Hip circumference (cm)
measured with a tape measure around the greater trochanteric prominence (the widest part of the hips)
Change in Hip circumference (cm)
measured with a tape measure around the greater trochanteric prominence (the widest part of the hips)
Change in Hip circumference (cm)
measured with a tape measure around the greater trochanteric prominence (the widest part of the hips)
Change in Waist to hip ratio
Ratio of waist circumference to hip circumference
Change in Waist to hip ratio
Ratio of waist circumference to hip circumference
Change in Waist to hip ratio
Ratio of waist circumference to hip circumference
Change in Blood leptin (ng/mL)
Fasting level of leptin in the blood
Change in Blood adiponectin (mcg/mL)
Fasting level of adiponectin in the blood
Change in Total cholesterol (mg/dL)
Fasting level of total cholesterol in blood
Change in Total cholesterol (mg/dL)
Fasting level of total cholesterol in blood
Change in Total cholesterol (mg/dL)
Fasting level of total cholesterol in blood
Change in low-density lipoprotein (LDL) Cholesterol (mg/dL)
Fasting level of LDL cholesterol in blood
Change in low-density lipoprotein (LDL) Cholesterol (mg/dL)
Fasting level of LDL cholesterol in blood
Change in low-density lipoprotein (LDL) Cholesterol (mg/dL)
Fasting level of LDL cholesterol in blood
Change in high-density lipoprotein (HDL) Cholesterol (mg/dL)
Fasting level of HDL cholesterol in blood
Change in high-density lipoprotein (HDL) Cholesterol (mg/dL)
Fasting level of HDL cholesterol in blood
Change in high-density lipoprotein (HDL) Cholesterol (mg/dL)
Fasting level of HDL cholesterol in blood
Change in oxidized LDL (Ox-LDL) Cholesterol (U/L)
Fasting level of Ox-LDL cholesterol in blood
Change in oxidized LDL (Ox-LDL) Cholesterol (U/L)
Fasting level of Ox-LDL cholesterol in blood
Change in oxidized LDL (Ox-LDL) Cholesterol (U/L)
Fasting level of Ox-LDL cholesterol in blood
Change in triglycerides (mg/dL)
Fasting level of triglycerides in blood
Change in triglycerides (mg/dL)
Fasting level of triglycerides in blood
Change in triglycerides (mg/dL)
Fasting level of triglycerides in blood
Change in Insulin (IU)
Fasting level of insulin in blood
Change in Insulin (IU)
Fasting level of insulin in blood
Change in Insulin (IU)
Fasting level of insulin in blood
Change in Glucose (mmol/L)
Fasting level of glucose in blood
Change in Glucose (mmol/L)
Fasting level of glucose in blood
Change in Glucose (mmol/L)
Fasting level of glucose in blood
Change in blood glycated haemoglobin (HbA1c) (mmol/mol)
Fasting level of HbA1c in blood
Change in gut microbiota composition
Genera of bacteria measured in stool samples

Full Information

First Posted
February 16, 2017
Last Updated
January 31, 2019
Sponsor
Beachbody
Collaborators
KGK Science Inc., Glycemic Index Laboratories, Inc, MB Clinical Research and Consulting LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT03057873
Brief Title
The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss
Official Title
A Double Blind, Placebo Controlled Parallel Study to Investigate the Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss in Healthy Overweight Adults
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
February 13, 2017 (Actual)
Primary Completion Date
October 25, 2018 (Actual)
Study Completion Date
October 25, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beachbody
Collaborators
KGK Science Inc., Glycemic Index Laboratories, Inc, MB Clinical Research and Consulting LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The objective of this study is to investigate the effect of a high protein, high fiber dietary supplement on weight and fat loss in healthy overweight adults. Half of participants will receive a high protein, high fiber supplement twice a day for 12 weeks, and half of the subjects will receive a placebo (that contains the same amount of calories as the supplement) twice a day for 12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight
Keywords
protein, fiber, weight loss, fat loss

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double-blind
Allocation
Randomized
Enrollment
206 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High protein, high fiber
Arm Type
Experimental
Arm Description
Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
Arm Title
Low protein, low fiber
Arm Type
Placebo Comparator
Arm Description
Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
High protein, high fiber dietary supplement
Intervention Description
Dry powder to be mixed with 10 ounces of cold water
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Dry powder to be mixed with 10 ounces of cold water
Primary Outcome Measure Information:
Title
Change in body weight (kg)
Description
Body weight measured by clinic study staff at required visits
Time Frame
Baseline and 12 weeks
Title
Change in body fat percentage (%)
Description
Body fat percentage as determined by dual x-ray absorptiometry (DXA)
Time Frame
Baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Change in total fat mass (kg)
Description
Body fat mass as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in total lean mass (kg)
Description
Body lean mass as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in percent abdominal fat (%)
Description
Abdominal fat percentage as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in percent android fat (%)
Description
Android fat percentage as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in percent gynoid fat (%)
Description
Gynoid fat percentage as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in percent trunk fat (%)
Description
Trunk fat percentage as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in percent leg fat (%)
Description
Leg fat percentage as determined by DXA
Time Frame
Baseline and 12 weeks
Title
Change in body weight (kg)
Description
Body weight measured by clinic study staff at required visits
Time Frame
Baseline and 4 weeks
Title
Change in body weight (kg)
Description
Body weight measured by clinic study staff at required visits
Time Frame
Baseline and 8 weeks
Title
Change in Waist circumference (cm)
Description
measured with a tape measure at the part of the trunk located midway between the lower costal margin and the iliac crest while the person is standing
Time Frame
Baseline and 4 weeks
Title
Change in Waist circumference (cm)
Description
measured with a tape measure at the part of the trunk located midway between the lower costal margin and the iliac crest while the person is standing
Time Frame
Baseline and 8 weeks
Title
Change in Waist circumference (cm)
Description
measured with a tape measure at the part of the trunk located midway between the lower costal margin and the iliac crest while the person is standing
Time Frame
Baseline and 12 weeks
Title
Change in Hip circumference (cm)
Description
measured with a tape measure around the greater trochanteric prominence (the widest part of the hips)
Time Frame
Baseline and 4 weeks
Title
Change in Hip circumference (cm)
Description
measured with a tape measure around the greater trochanteric prominence (the widest part of the hips)
Time Frame
Baseline and 8 weeks
Title
Change in Hip circumference (cm)
Description
measured with a tape measure around the greater trochanteric prominence (the widest part of the hips)
Time Frame
Baseline and 12 weeks
Title
Change in Waist to hip ratio
Description
Ratio of waist circumference to hip circumference
Time Frame
Baseline and 4 weeks
Title
Change in Waist to hip ratio
Description
Ratio of waist circumference to hip circumference
Time Frame
Baseline and 8 weeks
Title
Change in Waist to hip ratio
Description
Ratio of waist circumference to hip circumference
Time Frame
Baseline and 12 weeks
Title
Change in Blood leptin (ng/mL)
Description
Fasting level of leptin in the blood
Time Frame
Baseline and 12 weeks
Title
Change in Blood adiponectin (mcg/mL)
Description
Fasting level of adiponectin in the blood
Time Frame
Baseline and 12 weeks
Title
Change in Total cholesterol (mg/dL)
Description
Fasting level of total cholesterol in blood
Time Frame
Baseline and 4 weeks
Title
Change in Total cholesterol (mg/dL)
Description
Fasting level of total cholesterol in blood
Time Frame
Baseline and 8 weeks
Title
Change in Total cholesterol (mg/dL)
Description
Fasting level of total cholesterol in blood
Time Frame
Baseline and 12 weeks
Title
Change in low-density lipoprotein (LDL) Cholesterol (mg/dL)
Description
Fasting level of LDL cholesterol in blood
Time Frame
Baseline and 4 weeks
Title
Change in low-density lipoprotein (LDL) Cholesterol (mg/dL)
Description
Fasting level of LDL cholesterol in blood
Time Frame
Baseline and 8 weeks
Title
Change in low-density lipoprotein (LDL) Cholesterol (mg/dL)
Description
Fasting level of LDL cholesterol in blood
Time Frame
Baseline and 12 weeks
Title
Change in high-density lipoprotein (HDL) Cholesterol (mg/dL)
Description
Fasting level of HDL cholesterol in blood
Time Frame
Baseline and 4 weeks
Title
Change in high-density lipoprotein (HDL) Cholesterol (mg/dL)
Description
Fasting level of HDL cholesterol in blood
Time Frame
Baseline and 8 weeks
Title
Change in high-density lipoprotein (HDL) Cholesterol (mg/dL)
Description
Fasting level of HDL cholesterol in blood
Time Frame
Baseline and 12 weeks
Title
Change in oxidized LDL (Ox-LDL) Cholesterol (U/L)
Description
Fasting level of Ox-LDL cholesterol in blood
Time Frame
Baseline and 4 weeks
Title
Change in oxidized LDL (Ox-LDL) Cholesterol (U/L)
Description
Fasting level of Ox-LDL cholesterol in blood
Time Frame
Baseline and 8 weeks
Title
Change in oxidized LDL (Ox-LDL) Cholesterol (U/L)
Description
Fasting level of Ox-LDL cholesterol in blood
Time Frame
Baseline and 12 weeks
Title
Change in triglycerides (mg/dL)
Description
Fasting level of triglycerides in blood
Time Frame
Baseline and 4 weeks
Title
Change in triglycerides (mg/dL)
Description
Fasting level of triglycerides in blood
Time Frame
Baseline and 8 weeks
Title
Change in triglycerides (mg/dL)
Description
Fasting level of triglycerides in blood
Time Frame
Baseline and 12 weeks
Title
Change in Insulin (IU)
Description
Fasting level of insulin in blood
Time Frame
Baseline and 4 weeks
Title
Change in Insulin (IU)
Description
Fasting level of insulin in blood
Time Frame
Baseline and 8 weeks
Title
Change in Insulin (IU)
Description
Fasting level of insulin in blood
Time Frame
Baseline and 12 weeks
Title
Change in Glucose (mmol/L)
Description
Fasting level of glucose in blood
Time Frame
Baseline and 4 weeks
Title
Change in Glucose (mmol/L)
Description
Fasting level of glucose in blood
Time Frame
Baseline and 8 weeks
Title
Change in Glucose (mmol/L)
Description
Fasting level of glucose in blood
Time Frame
Baseline and 12 weeks
Title
Change in blood glycated haemoglobin (HbA1c) (mmol/mol)
Description
Fasting level of HbA1c in blood
Time Frame
Baseline and 12 weeks
Title
Change in gut microbiota composition
Description
Genera of bacteria measured in stool samples
Time Frame
Baseline and 12 weeks
Other Pre-specified Outcome Measures:
Title
Change in Modified Gastrointestinal Symptoms Rating Scale (GSRS) dimensions
Description
Score on each of the 6 dimensions contained in the validated Modified GSRS tool (scores 1-7)
Time Frame
Baseline and 4 weeks
Title
Change in Modified Gastrointestinal Symptoms Rating Scale (GSRS) dimensions
Description
Score on each of the 6 dimensions contained in the validated Modified GSRS tool (scores 1-7)
Time Frame
Baseline and 8 weeks
Title
Change in Modified Gastrointestinal Symptoms Rating Scale (GSRS) dimensions
Description
Score on each of the 6 dimensions contained in the validated Modified GSRS tool (scores 1-7)
Time Frame
Baseline and 12 weeks
Title
Change in Bowel Habits (number of bowel movements/day; Bristol Stool form type)
Description
Bowel habits assessed for 72-hour period every 2 weeks by bowel habits diary including number of bowel movements per day and classification of stool form type. Data for each time point (4, 8, and 12 weeks) will include 2 diary collections.
Time Frame
Baseline and 4 weeks
Title
Change in Bowel Habits (number of bowel movements/day; Bristol Stool form type)
Description
Bowel habits assessed for 72-hour period every 2 weeks by bowel habits diary including number of bowel movements per day and classification of stool form type. Data for each time point (4, 8, and 12 weeks) will include 2 diary collections.
Time Frame
Baseline and 8 weeks
Title
Change in Bowel Habits (number of bowel movements/day; Bristol Stool form type)
Description
Bowel habits assessed for 72-hour period every 2 weeks by bowel habits diary including number of bowel movements per day and classification of stool form type. Data for each time point (4, 8, and 12 weeks) will include 2 diary collections.
Time Frame
Baseline and 12 weeks
Title
Change in systolic blood pressure
Description
Seated resting blood pressure will be determined from 3 measurements obtained at least 1 minute apart
Time Frame
Baseline and 4 weeks
Title
Change in systolic blood pressure
Description
Seated resting blood pressure will be determined from 3 measurements obtained at least 1 minute apart
Time Frame
Baseline and 8 weeks
Title
Change in systolic blood pressure
Description
Seated resting blood pressure will be determined from 3 measurements obtained at least 1 minute apart
Time Frame
Baseline and 12 weeks
Title
Change in diastolic blood pressure
Description
Seated resting blood pressure will be determined from 3 measurements obtained at least 1 minute apart
Time Frame
Baseline and 4 weeks
Title
Change in diastolic blood pressure
Description
Seated resting blood pressure will be determined from 3 measurements obtained at least 1 minute apart
Time Frame
Baseline and 8 weeks
Title
Change in diastolic blood pressure
Description
Seated resting blood pressure will be determined from 3 measurements obtained at least 1 minute apart
Time Frame
Baseline and 12 weeks
Title
Change in Profiles of Mood States (POMS) questionnaire ratings
Description
Scores for energy, mood, and stress as assessed by POMS questionnaire
Time Frame
Baseline and 4 weeks
Title
Change in Profiles of Mood States (POMS) questionnaire ratings
Description
Scores for energy, mood, and stress as assessed by POMS questionnaire
Time Frame
Baseline and 8 weeks
Title
Change in Profiles of Mood States (POMS) questionnaire ratings
Description
Scores for energy, mood, and stress as assessed by POMS questionnaire
Time Frame
Baseline and 12 weeks
Title
Change in Three-factor Eating Questionnaire (TFEQ) scores
Description
Scores for eating behavior as assessed by TFEQ
Time Frame
Baseline and 4 weeks
Title
Change in Three-factor Eating Questionnaire (TFEQ) scores
Description
Scores for eating behavior as assessed by TFEQ
Time Frame
Baseline and 8 weeks
Title
Change in Three-factor Eating Questionnaire (TFEQ) scores
Description
Scores for eating behavior as assessed by TFEQ
Time Frame
Baseline and 12 weeks
Title
Change in Binge Eating Scale (BES) scores
Description
Scores for binge eating as assessed by BES
Time Frame
Baseline and 4 weeks
Title
Change in Binge Eating Scale (BES) scores
Description
Scores for binge eating as assessed by BES
Time Frame
Baseline and 8 weeks
Title
Change in Binge Eating Scale (BES) scores
Description
Scores for binge eating as assessed by BES
Time Frame
Baseline and 12 weeks
Title
Change in number of junk food cravings reported
Description
Number of cravings as assessed by daily entries in study diary
Time Frame
Baseline and 4 weeks
Title
Change in number of junk food cravings reported
Description
Number of cravings as assessed by daily entries in study diary
Time Frame
Baseline and 8 weeks
Title
Change in number of junk food cravings reported
Description
Number of cravings as assessed by daily entries in study diary
Time Frame
Baseline and 12 weeks
Title
Change in IgG levels
Description
Fasting level of IgG in blood
Time Frame
Baseline and 12 weeks
Title
Change in IgA levels
Description
Fasting level of IgA in blood
Time Frame
Baseline and 12 weeks
Title
Change in IgM levels
Description
Fasting level of IgM in blood
Time Frame
Baseline and 12 weeks
Title
Change in Complement C3 levels
Description
Fasting level of C3 in blood
Time Frame
Baseline and 12 weeks
Title
Change in Complement C4 levels
Description
Fasting level of C4 in blood
Time Frame
Baseline and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female of 25-50 years of age If female, the subject is not of child bearing potential, which is defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result at screening. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) for at least 3 months Double-barrier method Non-hormonal IUDs Hormonal IUD methods must be a stable dose for at least 3 months Vasectomy of partner Non-heterosexual lifestyle A BMI between 27.0 - <35.0 kg/m2 (inclusive). Subjects must meet exactly the inclusion BMI at screening, or be screen failed. Subjects who meet the BMI requirement at screening and present at run-in with a BMI of <27.0 or >35 kg/m2 will be counselled. Subjects that have had a stable weight for the past 6 months. A stable weight is defined as not having gained or lost more than 5 kg of body weight throughout the past 6 months (cycling of weight, for example, continuously up and down anything less than 5 kg is considered stable) Agreement to comply with dietary recommendations from nutritionist throughout the duration of the study that include a 500 kcal energy deficit from their predicted total energy requirements Agrees to fully comply with all study procedures Has given voluntary written and informed consent to participate in the study Determined to be healthy as per laboratory parameters and physical examination Exclusion Criteria: Females who are pregnant, breastfeeding or planning to become pregnant during the course of the study Subjects who are smokers (tobacco, e-cigarettes) or have been a smoker within the past 1 year from screening Individuals who carry an epi-pen, or those with a diagnosed allergy or who believe that they have an allergy to milk or milk products, crustacean shellfish, tree nuts, or peanuts Individuals with a severe allergy to egg, fish, wheat or soy ingredients as the product is manufactured in a facility that contains these ingredients The use of prescription, over-the-counter health products, or natural health products/dietary supplements being taken for weight loss, cholesterol levels, or blood pressure within 4 weeks of screening Subjects with a history of eating disorders Current participation or participation within the last 3 months in any weight loss program or diet (for example Weight Watchers, Jenny Craig, DASH diet, Atkins, Mediterranean etc.) Medical history of thyroid disorders except for subjects diagnosed with hypothyroid and have been on stable medication for at least the last 3 months prior to enrollment. All subject with medical history of hyperthyroid are excluded Medical history of hypercholesterolipidemia Use of cholesterol lowering prescription drugs within the last 6 months Fasting TGs ≥ 200 mg/dL (2.26 mmol/L) or a fasting total cholesterol ≥ 240 mg/dL (6.216 mmol/L) Fasting glucose ≥ 126 mg/dL Hypertension defined as untreated systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg, or the use of prescription high blood pressure/hypertension medications within the last 6 months Type I or Type II diabetes or use of diabetes medication in a preventative setting. History of gastrointestinal dysfunction or surgery that may influence digestion or absorption Chronic inflammation or structural abnormality, including history of, of the digestive tract (inflammatory bowel disease, celiac disease, chronic diarrhea, chronic constipation, duodenal or gastric ulcer, gastric retention or obstruction, Gastroesophageal reflux disease (GERD), or symptomatic cholelithiasis) Subjects who have a history of colorectal cancer, bowel resection, rectocele, or colostomy Immunocompromised individuals such as subjects that have undergone organ transplantation, those with rheumatoid arthritis, or subjects diagnosed with human immunodeficiency virus (HIV) Unstable medical conditions that in the opinion of the Qualified Investigator preclude the subject from participating in the study Anti-anxiety and anti-psychotic medications will be assessed by the MD on a case by case basis Alcohol use > 2 standard alcoholic drinks per day Alcohol or drug abuse within the last 6 months Use of medicinal marijuana Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative Subjects with metal fixation plates or screws from a previous surgery Clinically significant abnormal laboratory results at screening Participation in a clinical research trial within 30 days prior to randomization Allergy or sensitivity to study supplement ingredients Individuals who are cognitively impaired and/or who are unable to give informed consent Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject Unwilling or unable to comply with study timeline and procedures Individuals who do not like the taste of chocolate or shake type drinks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Crowley, MD
Organizational Affiliation
KGK Science Inc.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Thomas Wolever, MD, PhD
Organizational Affiliation
Glycemic Index Laboratories, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rupal Trivedi, MD
Organizational Affiliation
Great Lakes Clinical Trials (of MB Clinical Research and Consulting, LLC)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Great Lakes Clinical Trials (of MB Clinical Research and Consulting, LLC)
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60630
Country
United States
Facility Name
KGK Synergize Inc.
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 58R
Country
Canada
Facility Name
GI Labs, Inc.
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5C 2N8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
35212740
Citation
Glynn EL, Fleming SA, Edwards CG, Wilson MJ, Evans M, Leidy HJ. Consuming a Protein and Fiber-Based Supplement Preload Promotes Weight Loss and Alters Metabolic Markers in Overweight Adults in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. J Nutr. 2022 Jun 9;152(6):1415-1425. doi: 10.1093/jn/nxac038.
Results Reference
derived

Learn more about this trial

The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss

We'll reach out to this number within 24 hrs